Core Viewpoint - Fuhong Hanlin's stock price surged over 8%, reaching a historical high of 89 HKD, and currently stands at 85.55 HKD with a trading volume of 99.13 million HKD, following the announcement of the first prescription for its innovative small molecule CDK4/6 inhibitor, Fuzhoning [1] Group 1 - Fuhong Hanlin announced that its small molecule CDK4/6 inhibitor, Fuzhoning (Citrus Acid Vovisil Capsules), has received its first prescription from over ten hospitals across China, including Fudan University Shanghai Cancer Center and Zhejiang University School of Medicine First Affiliated Hospital [1] - Fuzhoning, in combination with Fulvestrant, is indicated for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) recurrent or metastatic breast cancer patients who have experienced disease progression after prior endocrine therapy [1] - The drug is owned by Jinjou Aohong Pharmaceutical, a subsidiary of Fosun Pharma, while Fuhong Hanlin is responsible for its commercialization in China [1]
复宏汉霖盘中涨超8% 股价再创历史新高-港股-金融界